Oric Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2022-02-01

Reporting Person: Chacko Jacob (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-01	Stock Option (right to buy)	$9.48	A	300000	Acquired	2032-01-31	Common Stock (300000)	Direct
2022-02-01	Restricted Stock Unit	$	A	50000	Acquired		Common Stock (50000)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on February 1, 2023, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

F3: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.